作者
Maria Domenica Cappellini,Vip Viprakasit,Alì Taher,Pencho Georgiev,Kevin H.M. Kuo,Thomas D. Coates,Ersi Voskaridou,Hong-Keng Liew,Idit Pazgal-Kobrowski,Gian Luca Forni,Silverio Perrotta,Abderrahim Khélif,Ashutosh Lal,Antonis Kattamis,Efthymia Vlachaki,Raffaella Origa,Yeşim Aydınok,Mohamed Béjaoui,P. Joy Ho,Lee-Ping Chew,Ping Chong Bee,Soo-min Lim,Meng‐Yao Lu,Adisak Tantiworawit,Penka Ganeva,Liana Gercheva,Androulla Eleftheriou,Ellis J. Neufeld,Alexis A. Thompson,Abderrahmane Laadem,Jeevan K. Shetty,Jun Zou,Jennie Zhang,Dimana Miteva,Tatiana Zinger,Peter G. Linde,Matthew L. Sherman,Olivier Hermine,John B. Porter,Antonio Piga
摘要
Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients.